Home / Intelligence / Case Studies / Mapping Payer & Employer Perceptions of Novel Migraine Therapies to Support Access Strategy Development
Trinity conducted a payer and employer advisory board to understand current perceptions of novel migraine therapies and potential strategies to improve access.
Geographic Scope: 
Client Situation
The client wanted to gather the payer and employer perspective on how the migraine landscape is evolving, and pressure test key strategic options as well as messages that they had developed. The employers included: Coca-Cola Company, Metro Nashville Public Schools, St. Louis Community College, and Vibra Healthcare.
Trinity’s Solution
Trinity conducted an unblinded advisory board with a diverse set of payers and employee benefit managers to understand current perceptions of the migraine landscape and the employer interaction with payers as it pertains to influencing employee access to novel migraine therapies.
Deliverables
- Moderator Guide targeting each advisory board stakeholder
- Pre-Survey and Workbook materials designed to capture individual data responses
- Two advisory board sessions where the client played an active role – including individual payer and employer breakout sessions
- Final Report and Executive Summary synthesizing live / written payer and employer insights, highlighting strategic opportunities, challenges, and recommendations
Project Outcomes & Impact
Bringing together both payers and employers into an ad board setting created a real-world dynamic that is not often simulated through market research activities. The feedback within the section on “Cross-Stakeholder Approaches to Engagement on Migraine” provided the client with clear insights on how to effectively engage both stakeholder groups, with a primary output being a tool that payers can use to educate their employer clients on costs associated with migraine and to inform them on how to mitigate costs for their organizations.
Related Intelligence
Blog
Learnings to Kick-Start 2025: Health Equity
Health equity continues to be a hot topic in the life sciences industry. ISPOR EU sessions addressed several key questions surrounding the impact of health equity on HTA decision-making, the methodologies that should be employed, and the opportunities and challenges of incorporating health equity into health technology assessment (HTA). Ahead of ISPOR EU, Trinity’s HTA […]
Read More
Blog
Maximum Fair Price Round 2: Passing the Baton
On January 20, 2025, CMS announced the set of fifteen drugs targeted for the second round of Maximum Fair Price (MFP) “negotiations” under IRA. With the outcomes of the first price “negotiations” announced only last August, the IRA MFP process is still in its early development and there remains uncertainty over how it will evolve […]
Read More
Blog
Solving the Cell & Gene Therapy Access Puzzle in the U.S.
Cell and gene therapies (CGTs) have ushered in a new era of medicine, offering patients transformative, even potentially curative solutions, with a single treatment. Despite the clinical promise, barriers to patient access remain given administration complexity, gaps in patient outcome evidence and high costs. As cell and gene therapies become available in new indications beyond […]
Read More